255 related articles for article (PubMed ID: 28646771)
1. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
2. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim DW; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC; Han JY; Bordogna W; Golding S; Zeaiter A; Ou SI
J Clin Oncol; 2016 Dec; 34(34):4079-4085. PubMed ID: 27863201
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K;
Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536
[TBL] [Abstract][Full Text] [Related]
4. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Morcos PN; Nueesch E; Jaminion F; Guerini E; Hsu JC; Bordogna W; Balas B; Mercier F
Cancer Chemother Pharmacol; 2018 Jul; 82(1):129-138. PubMed ID: 29748847
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
Hida T; Seto T; Horinouchi H; Maemondo M; Takeda M; Hotta K; Hirai F; Kim YH; Matsumoto S; Ito M; Ayukawa K; Tokushige K; Yonemura M; Mitsudomi T; Nishio M
Cancer Sci; 2018 Sep; 109(9):2863-2872. PubMed ID: 29959809
[TBL] [Abstract][Full Text] [Related]
6. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
Yang JC; Liu G; Lu S; He J; Burotto M; Ahn MJ; Kim DW; Liu X; Zhao Y; Vincent S; Yin J; Ma X; Lin HM; Popat S
J Thorac Oncol; 2023 Dec; 18(12):1743-1755. PubMed ID: 37574132
[TBL] [Abstract][Full Text] [Related]
7. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract][Full Text] [Related]
9. Alectinib in Resected
Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study.
Liu Q; Fu Y; Guo J; Fu C; Tang N; Zhang C; Han X; Wang Z
Oncol Lett; 2024 May; 27(5):224. PubMed ID: 38586212
[TBL] [Abstract][Full Text] [Related]
11. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.
Gainor JF; Chi AS; Logan J; Hu R; Oh KS; Brastianos PK; Shih HA; Shaw AT
J Thorac Oncol; 2016 Feb; 11(2):256-60. PubMed ID: 26845119
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.
Lei YY; Yang JJ; Zhong WZ; Chen HJ; Yan HH; Han JF; Yang LL; Wu YL
J Thorac Dis; 2015 Jul; 7(7):1181-8. PubMed ID: 26380734
[TBL] [Abstract][Full Text] [Related]
13. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib.
Cheung JM; Kang J; Yeap BY; Peterson JL; Do A; Gainor JF; Digumarthy SR; Lin JJ
JTO Clin Res Rep; 2024 Mar; 5(3):100645. PubMed ID: 38425547
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy versus alectinib for the treatment of crizotinib-pretreated ALK-positive patients with non small cell lung cancer: A protocol for systematic review and meta-analysis.
Gao T; Li C; He X; Zhang T
Medicine (Baltimore); 2022 Mar; 101(11):. PubMed ID: 35356928
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Alectinib in
Passaro A; Peters S
N Engl J Med; 2024 Apr; 390(14):1325-1327. PubMed ID: 38598800
[No Abstract] [Full Text] [Related]
17. Alectinib continuation beyond progression in
Li Y; Hao Z; Ma Y; Setiwalidi K; Zhang Y; Zhao Y; Fu X; Liang X; Ruan Z; Tian T; Yao Y
Transl Lung Cancer Res; 2024 Jan; 13(1):152-162. PubMed ID: 38405000
[TBL] [Abstract][Full Text] [Related]
18. Intracranial Efficacy of Selpercatinib in
Subbiah V; Gainor JF; Oxnard GR; Tan DSW; Owen DH; Cho BC; Loong HH; McCoach CE; Weiss J; Kim YJ; Bazhenova L; Park K; Daga H; Besse B; Gautschi O; Rolfo C; Zhu EY; Kherani JF; Huang X; Kang S; Drilon A
Clin Cancer Res; 2021 Aug; 27(15):4160-4167. PubMed ID: 34088726
[TBL] [Abstract][Full Text] [Related]
19. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
Abdallah SM; Wong A
Curr Oncol; 2018 Jun; 25(Suppl 1):S103-S114. PubMed ID: 29910653
[TBL] [Abstract][Full Text] [Related]
20. TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis.
Qin J; Li R; Ma H; Ding P; Yang Q; Hu L; Wu D; Xiong S
Medicine (Baltimore); 2023 Jul; 102(29):e34138. PubMed ID: 37478272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
